- Home
- WFC vs AZN Comparison
WFC vs AZN Comparison
Compare WFC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFC | AZN |
|---|---|---|
| Founded | 1852 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6B | 283.9B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | WFC | AZN |
|---|---|---|
| Price | $94.14 | $95.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 2 |
| Target Price | ★ $94.11 | N/A |
| AVG Volume (30 Days) | ★ 12.6M | 4.8M |
| Earning Date | 01-14-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.87% | 1.62% |
| EPS Growth | 26.82 | ★ 45.02 |
| EPS | ★ 6.07 | 6.02 |
| Revenue | ★ $79,072,000,000.00 | $58,127,000,000.00 |
| Revenue This Year | $8.89 | $11.40 |
| Revenue Next Year | $5.27 | $6.06 |
| P/E Ratio | $15.88 | ★ $15.78 |
| Revenue Growth | 1.54 | ★ 13.52 |
| 52 Week Low | $58.42 | $61.24 |
| 52 Week High | $97.76 | $95.27 |
Technical Indicators
Market Signals| Indicator | WFC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 56.78 | 66.19 |
| Support Level | $92.81 | $89.53 |
| Resistance Level | $97.76 | $93.10 |
| Average True Range (ATR) | 1.55 | 1.31 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 41.62 | 77.65 |
Price Performance
Historical ComparisonAbout WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $2.0 trillion in balance-sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US market.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.